Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01305746 · ClinicalTrials.gov registry record · Phase 2
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 382
- Enrollment target
- 20
- Study locations
NCT01305746 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 382 participants, roughly in line with the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT01305746, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 382 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
Conditions Studied
Interventions
- DRUG A-623
Study Locations (20)
Buenos Aires
- Investigator Site 404 - Caba
- Investigator Site 402 - Caba
- Investigator Site 407 - Caba
- Investigator Site 401 - Caba
California
- Investigator Site 113 - Long Beach
- Investigator Site 110 - Upland
Florida
- Investigator Site 105 - Orlando
- Investigator Site 102 - Tampa
New York
- Investigator Site 106 - Lake Success
- Investigator Site 114 - Smithtown
Oklahoma
- Investigator Site 112 - Oklahoma City
- Investigator Site 111 - Tulsa
Alabama
- Investigator Site 103 - Birmingham
Maryland
- Investigator Site 117 - Baltimore
Michigan
- Investigator Site 104 - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 382 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01305746
The ClinicalTrials.gov registry entry for NCT01305746 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 382 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 376-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target. The listed sponsor is Anthera Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which A-623 is the first listed.
NCT01305746 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Buenos Aires, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01305746 about?
NCT01305746 is a clinical study titled "A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321". The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.
What is the current status of trial NCT01305746?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 382 participants. The study started on 2011-04. Estimated completion is 2013-10.
What conditions does trial NCT01305746 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT01305746?
The interventions under investigation include: A-623 (DRUG).
Who is sponsoring clinical trial NCT01305746?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01305746 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.